Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma.

Blood·2026

Same author

System-Level Redesign of an Allogeneic Hematopoietic Cell Transplantation Program Associated with High 1-Year Survival and Reduced Cost.

Transplantation and cellular therapy·2026

Same author

TRAC in vivo: culmination of CAR and vector engineering.

Cell research·2026

Same author

Tumor irradiation promotes antigen dressing of dendritic cells to enhance CAR T cell persistence and efficacy in lung metastases.

Nature cancer·2026

Same author

Dual CAR-T cell therapy targeting CD19 and BCMA as a novel opportunity for immune reset in systemic lupus erythematosus.

Cellular & molecular immunology·2026

Same author

Development of a Fully Non-Viral 1XX-enhanced BCMA CAR-T Cell Therapy for Multiple Myeloma.

bioRxiv : the preprint server for biology·2026

Search research articles

Related Experiment Video

Updated: Apr 12, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

CD19 CAR Therapy for Acute Lymphoblastic Leukemia.

Michel Sadelain¹, Renier Brentjens¹, Isabelle Rivière¹

¹From the Center for Cell Engineering and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting

|May 21, 2015

Summary

Chimeric antigen receptor (CAR) therapy targeting CD19 shows high complete remission rates in acute lymphoblastic leukemia (ALL). This immunotherapy redirects T cells to destroy leukemia cells, offering a promising new cancer treatment option.

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Related Experiment Videos

Last Updated: Apr 12, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Area of Science:

Immunotherapy
Oncology
Cellular Therapy

Background:

Chimeric antigen receptor (CAR) therapy is an innovative immunotherapy approach.
CARs are engineered receptors that redirect T cell specificity and function.
CD19 is a validated target for CAR therapy in B cell malignancies.

Purpose of the Study:

To evaluate the efficacy of CD19-targeted CAR therapy for acute lymphoblastic leukemia (ALL).
To assess the potential of CAR therapy as a treatment for B cell malignancies.

Main Methods:

Genetic transfer of CARs into patient T lymphocytes.
T cells engineered to recognize and target CD19-expressing leukemia cells.

Main Results:

High complete remission rates observed in adults and children with ALL.
Efficacy is consistent across different age groups and prior treatment histories.
Management strategies exist for cytokine release syndrome, a potential side effect.

Conclusions:

CD19 CAR therapy demonstrates significant promise for treating B cell acute lymphoblastic leukemia.
This therapy is expected to become a standard treatment for B cell malignancies.
Further integration into the clinical armamentarium is anticipated.